2024 연구성과 (22 / 286)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
WoS SCOPUS Document Type Document Title Abstract Authors Affiliation ResearcherID (WoS) AuthorsID (SCOPUS) Author Email(s) Journal Name JCR Abbreviation ISSN eISSN Volume Issue WoS Edition WoS Category JCR Year IF JCR (%) FWCI ⓘ FWCI Update Date WoS Citation SCOPUS Citation Keywords (WoS) KeywordsPlus (WoS) Keywords (SCOPUS) KeywordsPlus (SCOPUS) Language Publication Stage Publication Year Publication Date DOI JCR Link DOI Link WOS Link SCOPUS Link
○ ○ Article ⓘ Lithium supercapacitors with environmentally-friend water-processable solid-state hybrid electrolytes of zinc oxide/polymer/lithium hydroxide ⓘ Environment-friendly and safe solid-state electrolytes are of utmost importance for energy storage devices, but no study has been reported on water-processable hybrid electrolytes that take advantage of both organic and inorganic components. Here, for the first time, we demonstrate that novel water-processable hybrid films, consisting of zinc oxide (ZnO) nanoparticle, lithium hydroxide (LiOH), and branched-poly(ethylene imine) (bPEI), act as efficient solid-state electrolytes for lithium supercapacitors. The ZnO:bPEI:LiOH (ZPL) hybrid so-lutions were prepared using water by varying ZnO molar ratios up to 60 mol% to the repeating unit of bPEI. The enhanced ionic conductivity (-1.36 mS/cm), which is higher than that of bPEI:LiOH electrolytes, was achieved at ZnO = 30 mol%. The best ZPL supercapacitors, exhibiting high performances of peak potential (2.0 V) and energy density (3.38 mWh/kg) upon charging at 0.4 mA/g only, could be stably operated over 1000 charging/ discharging cycles. Series connection of multiple ZPL supercapacitors delivered increased output potentials (-4.5 V from three devices in series) with reproducible charging/discharging performances. The experimental result supports that the present ZPL hybrid electrolyte technology paves the way for eco-friendly processes of next-generation solid-state electrolytes that can be a key in safe energy storage devices for applications to electrical vehicles etc. ⓘ Murukadas, Deepu; Cho, Yeonhwa; Lee, Woongki; Lee, Sooyong; Kim, Hwajeong; Kim, Youngkyoo ⓘ Kyungpook Natl Univ, Organ Nanoelect Lab, Daegu 41566, South Korea; Kyungpook Natl Univ, KNU Inst Nanophoton Applicat KINPA, Dept Chem Engn, Daegu 41566, South Korea; Kyungpook Natl Univ, Dept Energy Convergence & Climate Change, Daegu 41566, South Korea; Kyungpook Natl Univ, Inst Global Climate Change & Energy, Daegu 41566, South Korea; Kyungpook Natl Univ, Res Inst Environm Sci & Technol, Prior Res Ctr, Daegu 41566, South Korea ⓘ ⓘ 58787856000; 57542729800; 59041346100; 55421486100; 15520531700; 10340424400 ⓘ ykimm@knu.ac.kr; ⓘ ENERGY ⓘ ENERGY ⓘ 0360-5442 1873-6785 290 SCIE ENERGY & FUELS;THERMODYNAMICS ⓘ 2024 9.4 3.2 0.94 2025-05-07 ⓘ 4 5 Supercapacitors; Water-processable; Hybrid electrolytes; ZnO nanoparticle; bPEI; LiOH ⓘ GEL POLYMER ELECTROLYTE; IONIC-CONDUCTIVITY; ELECTROCHEMICAL PROPERTIES; MEMBRANES ⓘ bPEI; Hybrid electrolytes; LiOH; Supercapacitors; Water-processable; ZnO nanoparticle ⓘ Energy storage; Ethylene; II-VI semiconductors; Lithium compounds; Oxide films; Solid electrolytes; Supercapacitor; (LiOH), and branched-poly(ethylene imine); Environment friendly; Hybrid electrolytes; Organic components; Poly(ethyleneimine); Processable; Solid-state electrolyte; Water-processable; Zinc oxide nanoparticles; ZnO; chemical composition; electrolyte; energy storage; instrumentation; nanoparticle; performance assessment; polymer; ZnO nanoparticles ⓘ English 2024 2024-03-01 10.1016/j.energy.2023.129984 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Microfluidic Detection and Analysis of Microplastics Using Surface Nanodroplets ⓘ Detection of microplastics from water is crucial for various reasons, such as food safety monitoring, monitoring of the fate and transport of microplastics, and development of preventive measures for their occurrence. Currently, microplastics are detected by isolating them using filtration, separation by centrifugation, or membrane filtration, subsequently followed by analysis using well-established analytical methods, such as Raman spectroscopy. However, due to their variability in shape, color, size, and density, isolation using the conventional methods mentioned above is cumbersome and time-consuming. In this work, we show a surface-nanodroplet-decorated microfluidic device for isolation and analysis of small microplastics (diameter of 10 mu m) from water. Surface nanodroplets are able to capture nearby microplastics as water flows through the microfluidic device. Using a model microplastic solution, we show that microplastics of various sizes and types can be captured and visualized by using optical and fluorescence microscopy. More importantly, as the surface nanodroplets are pinned on the microfluidic channel, the captured microplastics can also be analyzed using a Raman spectroscope, which enables both physical (i.e., size and shape) and chemical (i.e., type) characterization of microplastics at a single-particle level. The technique shown here can be used as a simple, fast, and economical detection method for small microplastics. ⓘ Faramarzi, Paniz; Jang, Wonik; Oh, Donghyeon; Kim, Byeunggon; Kim, Ju Hyeon; You, Jae Bem ⓘ Kyungpook Natl Univ, Dept Energy Convergence & Climate Change, Daegu 41566, South Korea; Kyungpook Natl Univ, Dept Chem Engn, Daegu 41566, South Korea; Korea Res Inst Chem Technol, Interface Mat & Chem Engn Res Ctr, Daejeon 34114, South Korea ⓘ You, Jae Bem/C-6211-2019; You, Jae/C-6211-2019; Kim, Byeunggon/LXW-3860-2024 ⓘ 58089703600; 58926849500; 58927059300; 57850996900; 59087991700; 55619455300 ⓘ jb.you@knu.ac.kr; ⓘ ACS SENSORS ⓘ ACS SENSORS ⓘ 2379-3694 9 3 SCIE CHEMISTRY, ANALYTICAL;CHEMISTRY, MULTIDISCIPLINARY;NANOSCIENCE & NANOTECHNOLOGY ⓘ 2024 9.1 3.2 3.18 2025-05-07 ⓘ 9 10 microplastics; surface nanodroplets; interfacialadsorption; Raman analysis; microfluidic device ⓘ WATER; SEPARATION; FLOW ⓘ interfacial adsorption; microfluidic device; microplastics; Raman analysis; surface nanodroplets ⓘ Environmental Monitoring; Microfluidics; Microplastics; Plastics; Water; Water Pollutants, Chemical; Fluidic devices; Fluorescence microscopy; Microfiltration; Microplastic; Particle size analysis; microplastic; plastic; water; Food-safety; Interfacial adsorption; Microfluidic analysis; Microfluidic detection; Microfluidics devices; Microplastics; Nano-droplets; Raman analysis; Safety monitoring; Surface nanodroplet; environmental monitoring; microfluidics; water pollutant; Microfluidics ⓘ English 2024 2024-03-05 10.1021/acssensors.3c02627 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Power regulation of a wind farm through flexible operation of turbines using predictive control ⓘ Wind farms are becoming larger, presenting opportunities to improve their efficiency and effectiveness. Although wind farm control can be used to adjust a wind farm's power output to meet grid requirements, its development is restricted by the limited flexibility of wind turbine operation. Wind turbines are typically designed to operate at the power output determined by the wind speed, making it difficult to adjust their power output quickly and easily in response to changes in grid demand. Anew approach to wind farm control that provides full flexibility for both wind farms and turbines is proposed. This method adjusts the wind farm's power production using predictive control of each turbine to meet the grid demands. The power generated by each turbine is adjusted to achieve this, keeping fluctuation in the wind farm power output low. A wind farm simulation is conducted under varying wind speeds using the discretized C MEX Matlab/SIMULINK (R) model of the 5 MW Supergen turbine and the wind turbine model from NREL. The results demonstrate that the wind farm power output tracks a reference value that can beset by the grid. The results are also analyzed on the torque/speed plane, and they indicate that the turbines operate within their specified safe operating zones under both normal and gusty wind operating conditions at the same time. ⓘ Routray, Abhinandan; Hur, Sung-ho ⓘ Kyungpook Natl Univ, Sch Elect & Elect Engn, Daegu 41566, South Korea ⓘ ROUTRAY, ABHINANDAN/IVU-9009-2023 ⓘ 57200499011; 36455858700 ⓘ shur@knu.ac.kr; ⓘ ENERGY ⓘ ENERGY ⓘ 0360-5442 1873-6785 313 SCIE ENERGY & FUELS;THERMODYNAMICS ⓘ 2024 9.4 3.2 0.63 2025-05-07 ⓘ 3 3 Wind farm; Turbine control; Predictive control ⓘ COORDINATED CONTROL; REQUIREMENTS ⓘ Predictive control; Turbine control; Wind farm ⓘ Wind farm; Flexible operation; New approaches; Power output; Power production; Power regulation; Predictive control; Turbine control; Turbine operation; Wind farm; Wind speed; design; power generation; prediction; smart grid; wind farm; wind turbine; wind velocity; Windmill ⓘ English 2024 2024-12-30 10.1016/j.energy.2024.133917 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ SRGAN-enhanced unsafe operation detection and classification of heavy construction machinery using cascade learning ⓘ In the inherently hazardous construction industry, where injuries are frequent, the unsafe operation of heavy construction machinery significantly contributes to the injury and accident rates. To reduce these risks, this study introduces a novel framework for detecting and classifying these unsafe operations for five types of construction machinery. Utilizing a cascade learning architecture, the approach employs a Super-Resolution Generative Adversarial Network (SRGAN), Real-Time Detection Transformers (RT-DETR), self-DIstillation with NO labels (DINOv2), and Dilated Neighborhood Attention Transformer (DiNAT) models. The study focuses on enhancing the detection and classification of unsafe operations in construction machinery through upscaling low-resolution surveillance footage and creating detailed high-resolution inputs for the RT-DETR model. This enhancement, by leveraging temporal information, significantly improves object detection and classification accuracy. The performance of the cascaded pipeline yielded an average detection and first-level classification precision of 96%, a second-level classification accuracy of 98.83%, and a third-level classification accuracy of 98.25%, among other metrics. The cascaded integration of these models presents a well-rounded solution for near-real-time surveillance in dynamic construction environments, advancing surveillance technologies and significantly contributing to safety management within the industry. ⓘ Kim, Bubryur; An, Eui-Jung; Kim, Sungho; Preethaa, K. R. Sri; Lee, Dong-Eun; Lukacs, R. R. ⓘ Kyungpook Natl Univ, Sch Space Engn Sci, 80 Daehak Ro,Buk Gu, Daegu 41566, South Korea; Kyungpook Natl Univ, Dept Robot & Smart Syst Engn, 80 Daehak Ro,Buk Gu, Daegu 41566, South Korea; Kyungpook Natl Univ, Intelligent Construct Automat Ctr, 80,Daehak Ro,Buk Gu, Daegu 41566, South Korea; Vellore Inst Technol, Sch Comp Sci & Engn, Vellore 632014, India; Kyungpook Natl Univ, Sch Architectural Civil Environm & Energy Engn, 1370 Sangyegk Dong, Daegu 702701, South Korea ⓘ ⓘ 57198355299; 59216376900; 57194701745; 57214320928; 56605563300; 59215689800 ⓘ brkim@knu.ac.kr;babyofbear@gmail.com;gim529963@gmail.com;sripreethaa.kr@vit.ac.in;dolee@knu.ac.kr;rebekarachellukacs@gmail.com; ⓘ ARTIFICIAL INTELLIGENCE REVIEW ⓘ ARTIF INTELL REV ⓘ 0269-2821 1573-7462 57 8 SCIE COMPUTER SCIENCE, ARTIFICIAL INTELLIGENCE ⓘ 2024 13.9 3.2 1.58 2025-05-07 ⓘ 2 2 Smart construction sites; Unsafe operation detection; Safety management; Super-resolution generative adversarial network; Transformer ⓘ OCCUPATIONAL INJURIES; COSTS ⓘ Safety management; Smart construction sites; Super-resolution generative adversarial network; Transformer; Unsafe operation detection ⓘ Accident prevention; Construction equipment; Construction industry; Generative adversarial networks; Object detection; Optical resolving power; Classification accuracy; Construction machinery; Construction sites; Heavy construction; Safety management; Smart construction site; Super-resolution generative adversarial network; Superresolution; Transformer; Unsafe operation detection; Classification (of information) ⓘ English 2024 2024-07-13 10.1007/s10462-024-10839-7 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Sustainable strategy for converting plastic waste into energy over pyrolysis: A comparative study of fluidized-bed and fixed-bed reactors ⓘ This paper proposed a sustainable strategy for converting plastic waste into energy over pyrolysis to address the dual crises of environment and energy. A fluidized-bed reactor was designed for processing three different plastic waste (PP, LDPE and ABS). A product yield and properties from a fluidized bed system were comprehensively analyzed and compared with those from a fixed-bed system. The fluidized-bed reactor well converted ABS and PP wastes into pyrolysis fuel, exhibiting higher medium and low fraction (C5 - C22 of 89.17 % for ABS) as compared to the amount from a fixed bed reactor (84.7 %) whereas LDPE and PP resulted in the similar product yields in the range of C5 - C22 from both reactors. In case of LDPE, the given pyrolysis temperature (520 degrees C) was not feasible to properly process them into fuels so that dominant heavy oil (-67.4 %) were produced regardless of the reactor type. GCMS analysis indicated that ABS pyrolysis oil is mainly composed of aromatics, aromatic-N and olefins whereas PP pyrolysis oil mainly includes olefins, paraffins and oxygenated compounds. From the current study, a potential use of a fluidized-bed reactor for pyrolysis was evaluated to overcome the major limitations of conventional pyrolysis process. ⓘ Choi, Yujin; Wang, Shuang; Yoon, Young Min; Jang, Jae Jun; Kim, Daewook; Ryu, Ho-Jung; Lee, Doyeon; Won, Yooseob; Nam, Hyungseok; Hwang, Byungwook ⓘ Korea Inst Energy Res, Climate Change Technol Div, Daejeon 34129, South Korea; Kyungpook Natl Univ, Sch Mech Engn, Daegu 41950, South Korea; Hanbat Natl Univ, Dept Civil & Environm Engn, Daejeon 34158, South Korea ⓘ Ryu, Ho-Jung/AAV-3451-2020; Nam, Hyungseok/J-7458-2015; Yoon, Youngmin/MSZ-2536-2025 ⓘ 57734617200; 57216215741; 58701048400; 57553717800; 55569361600; 7202277238; 55881252900; 57212454920; 57190418228; 44461423600 ⓘ namhs219@knu.ac.kr;bwh@kier.re.kr; ⓘ ENERGY ⓘ ENERGY ⓘ 0360-5442 1873-6785 286 SCIE ENERGY & FUELS;THERMODYNAMICS ⓘ 2024 9.4 3.2 6.57 2025-04-16 ⓘ 26 26 Plastic waste; Pyrolysis oil; Fluidized-bed; Fixed-bed reactor; Naptha ⓘ THERMAL-DEGRADATION; BIO-OIL; OPTIMIZATION; TEMPERATURE; CRACKING; BATCH; FUEL ⓘ Fixed-bed reactor; Fluidized-bed; Naptha; Plastic waste; Pyrolysis oil ⓘ ABS resins; Chemical reactors; Crude oil; Fluid catalytic cracking; Fluidized bed furnaces; Galerkin methods; Heavy oil production; Olefins; Styrene; Supersaturation; Comparatives studies; Energy; Fixed bed reactor; Fixed-bed reactors; Fluidized bed reactors; Napthas; Plastics waste; Product yields; Pyrolysis oil; Sustainable strategies; activation energy; comparative study; heavy oil; plastic waste; pyrolysis; Fluidized beds ⓘ English 2024 2024-01-01 10.1016/j.energy.2023.129564 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Syngas production through CO2-mediated pyrolysis of polyoxymethylene ⓘ Plastics have become an integral part of our daily lives owing to their exceptional physicochemical properties, such as durability, low density, and cost-effectiveness, compared to traditional materials. However, the escalating production of plastics has resulted in a proportional increase in waste generation. This paper proposes environmentally benign valorization/disposal methods for plastic waste, with a particular focus on adopting a pyrolysis process that utilizes CO2 as a strategic reaction medium. As a case study, polyoxymethylene (POM), a widely used engineering plastic, was valorized through CO2-mediated pyrolysis. This study experimentally demonstrates the mechanistic effectiveness of CO2 in expediting the reaction kinetics of the thermal decomposition, specifically dehydrogenation and deoxygenation, of volatile matter derived from POM. The results revealed that employing CO2 as a reactant in the two-stage pyrolysis at 500 degrees C produced 30.47 mmol more syngas than under inert conditions. In conclusion, the strategic utilization of a two-stage pyrolysis process at 500 degrees C with CO2 as the reactant has emerged as an effective approach to the valorization of POM. This study contributes to developing sustainable methods for managing plastic waste by addressing environmental concerns and the need for efficient material recovery. ⓘ Kwon, Dohee; Choi, Dongho; Song, Hocheol; Lee, Jechan; Jung, Sungyup; Kwon, Eilhann E. ⓘ Hanyang Univ, Dept Earth Resources & Environm Engn, Seoul 04763, South Korea; Sungkyunkwan Univ, Dept Global Smart City, Suwon 16419, South Korea; Sungkyunkwan Univ, Sch Civil Architectural Engn & Landscape Architect, Suwon 16419, South Korea; Kyungpook Natl Univ, Dept Environm Engn, Daegu 41566, South Korea ⓘ Lee, Jechan/J-1229-2016; Choi, Dongho/LTY-8225-2024; Jung, Sungyup/GZG-6207-2022; Kwon, Eilhann/A-1225-2012; Song, Hocheol/ABD-7214-2021 ⓘ 57208275497; 57200013497; 56562122800; 57188712886; 55073290800; 9240622100 ⓘ ek2148@hanyang.ac.kr; ⓘ ENERGY ⓘ ENERGY ⓘ 0360-5442 1873-6785 304 SCIE ENERGY & FUELS;THERMODYNAMICS ⓘ 2024 9.4 3.2 0.63 2025-05-07 ⓘ 3 3 Circular economy; Waste valorization; Pyrolysis; Carbon dioxide; Polyoxymethylene ⓘ THERMAL-DEGRADATION; CARBON-DIOXIDE; PLASTIC WASTE; FTIR; OPPORTUNITIES; GASIFICATION; COMBUSTION; ADDITIVES; BEHAVIOR ⓘ Carbon dioxide; Circular economy; Polyoxymethylene; Pyrolysis; Waste valorization ⓘ Acetal resins; Carbon dioxide; Cost effectiveness; Elastomers; Physicochemical properties; Reaction kinetics; Synthesis gas; Circular economy; Daily lives; Integral part; Physicochemical property; Plastics waste; Polyoxymethylene; Pyrolysis process; Syngas production; Valorisation; Waste valorizations; carbon dioxide; plastic waste; polymer; pyrolysis; reaction kinetics; Pyrolysis ⓘ English 2024 2024-09-30 10.1016/j.energy.2024.132118 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Thermo-chemical disposal of plastic waste from end-of-life vehicles (ELVs) using CO2 ⓘ The source reduction of plastic waste could be an effective means to attenuate hazardous environmental problems triggered by microplastics. Energy recovery from plastic waste through thermochemical processes is a desirable valorization route. To realize the grand challenges, plastic waste derived from end-of-life vehicles (ELVs) was pyrolyzed. To propose a greener feature, CO2 was introduced as a mediator to maximize carbon allocation to the gaseous pyrogenic product (syngas) by CO2 reduction to CO and concurrent oxidation of volatile matter (VM) that was evolved from the thermolysis of plastic waste. As such, fundamental and systematic works were conducted to delineate the CO2 effects on conversion of VMs. This study experimentally proved that CO2 promotes thermal cracking in line with C-C bond scissions. However, the reaction rate for the conversion of CO2 and VM into CO via homogeneous reaction was not fast. Therefore, a Ni-based catalyst was employed to accelerate the reaction rate. However, there was coke deposition on the catalyst surface. To prevent coke formation, we chose a method to enhance CO2 reduction to CO and the oxidation of VM. Thus, three bimetallic catalysts were used for catalytic pyrolysis. Among the three bimetallic catalysts, Rh0.1Ni1/SiO2 was the most effective. ⓘ Kim, Jung -Hun; Jung, Sungyup; Lee, Taewoo; Tsang, Yiu Fai; Kwon, Eilhann E. ⓘ Hanyang Univ, Dept Earth Resources & Environm Engn, Seoul 04763, South Korea; Kyungpook Natl Univ, Dept Environm Engn, Daegu 41566, South Korea; Educ Univ Hong Kong, Dept Sci & Environm Studies, Tai Po, Hong Kong 999077, Peoples R China; Educ Univ Hong Kong, State Key Lab Marine Pollut, Tai Po, Hong Kong 999077, Peoples R China ⓘ ; LEE, TAEWOO/MXK-6996-2025; Jung, Sungyup/ABE-1493-2021; Tsang, Yiu/AAJ-2524-2020; Kwon, Eilhann/AGY-3339-2022 ⓘ 57204508711; 55073290800; 57194348573; 22954605700; 9240622100 ⓘ ek2148@hanyang.ac.kr; ⓘ ENERGY ⓘ ENERGY ⓘ 0360-5442 1873-6785 290 SCIE ENERGY & FUELS;THERMODYNAMICS ⓘ 2024 9.4 3.2 0 2025-05-07 ⓘ 0 0 Circular economy; Waste valorization; CO 2 utilization; Plastic waste; End-of-life vehicles (ELVs) ⓘ THERMAL-DEGRADATION; GAS; COMBUSTION; PHTHALATE; PRODUCTS; IR ⓘ Circular economy; CO<sub>2</sub> utilization; End-of-life vehicles (ELVs); Plastic waste; Waste valorization ⓘ Catalysts; Coke; Nickel; Nickel compounds; Reaction rates; Reduction; Solid wastes; Vehicles; Waste disposal; Bimetallic catalysts; Circular economy; CO 2 reduction; CO2 utilization; End-of-life vehicle; End-of-Life Vehicles; Plastics waste; Reactions rates; Volatile matters; Waste valorizations; biomass allocation; carbon dioxide; catalyst; cracking (chemistry); economic structure; reaction rate; reduction; valorization; waste disposal; Carbon dioxide ⓘ English 2024 2024-03-01 10.1016/j.energy.2023.130136 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Tranexamic Acid Can Reduce Early Tendon Adhesions After Rotator Cuff Repair and Is Not Detrimental to Tendon-Bone Healing: A Comparative Animal Model Study ⓘ Purpose: To determine the effects of topical tranexamic acid (TXA) administration on tendon adhesions, shoulder range of motion (ROM), and tendon healing in an acute rotator cuff repair rat model. Methods: A total of 20 Sprague Dawley rats were used. Tendon adhesion, ROM, and biomechanical and histological analysis of tendon-bone healing was conducted at 3 and 6 weeks after surgery. The rats underwent rotator cuff repair surgery on both shoulders and were administered TXA via subacromial injections. The tendon adhesion was evaluated macroscopically and histologically. Biomechanical tendon healing was measured using a universal testing machine, and histological analysis was quantified by H&E, Masson's trichrome, and picrosirius red staining. Results: At 3 weeks after surgery, the adhesion score was significantly lower in the TXA group (2.10 +/- 0.32) than in the control group (2.70 +/- 0.48) (P = .005), but there was no significant difference between the 2 groups at 6 weeks. Regarding ROM, compared with the control group, the TXA group showed significantly higher external rotation (36.35 degrees +/- 4.52 degrees vs 28.42 degrees +/- 4.66 degrees, P < .001) and internal rotation (45.35 degrees +/- 9.36 degrees vs 38.94 degrees +/- 5.23 degrees, P = .013) 3 weeks after surgery. However, at 6 weeks, there were no significant differences in external and internal rotation between the 2 groups. In the biomechanical analysis, no significant differences in gross examination (3 weeks, P = .175, 6 weeks, P = .295), load to failure (3 weeks, P = .117, 6 weeks, P = .295), or ultimate stress (3 weeks, P = .602, 6 weeks, P = .917) were noted between the 2 groups 3 and 6 weeks after surgery. In the histological analysis of tendon healing, no significant differences in the total score (3 weeks, P = .323, 6 weeks, P = .572) were found between the 2 groups 3 and 6 weeks after surgery. Conclusions: Topical TXA administration showed a beneficial effect in reducing tendon adhesions and improving ROM 3 weeks postoperatively and had no effect at 6 weeks. This suggests that additional intervention with TXA may be useful in achieving long-term improvement in shoulder stiffness. Additionally, TXA may increase tissue ground substance accumulation in the late postoperative period but does not adversely affect tendon-bone interface healing. Clinical Relevance: The use of TXA after rotator cuff repair has no effect on tendon-bone interface healing in clinical practice and can improve shoulder stiffness in the early postoperative period. Additional research on the long-term effects is needed. ⓘ Yoon, Jong Pil; Park, Sung-Jin; Kim, Dong-Hyun; Lee, Hyun Joo; Park, Eugene Jae Jin; Shim, Bum-Jin; Chung, Seung Ho; Kim, Jun Sung; Chung, Seok Won ⓘ Kyungpook Natl Univ Hosp, Dept Orthopaed Surg, 130 Dongdeok Ro, Daegu 41944, South Korea; Konkuk Univ, Dept Orthopaed Surg, Med Ctr, Seoul, South Korea ⓘ Kim, Jun Sung/AAI-1673-2020; Park, Eugene/P-1473-2018 ⓘ 36098548400; 58527890700; 57198637188; 58838750100; 55371642100; 57201499293; 57221219695; 58527890900; 37065938600 ⓘ knuhos_sh2@naver.com; ⓘ ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY ⓘ ARTHROSCOPY ⓘ 0749-8063 1526-3231 40 8 SCIE ORTHOPEDICS;SPORT SCIENCES;SURGERY ⓘ 2024 5.4 3.2 1.58 2025-05-07 ⓘ 2 2 ⓘ EXPRESSION; STIFFNESS; TEARS; INJECTION ⓘ ⓘ Administration, Topical; Animals; Antifibrinolytic Agents; Biomechanical Phenomena; Disease Models, Animal; Male; Range of Motion, Articular; Rats; Rats, Sprague-Dawley; Rotator Cuff; Rotator Cuff Injuries; Tissue Adhesions; Tranexamic Acid; Wound Healing; eosin; hematoxylin; isoflurane; mucin; tranexamic acid; antifibrinolytic agent; tranexamic acid; anesthesia; animal experiment; animal model; Article; biomechanics; cell structure; clinical practice; comparative study; controlled study; deltoid muscle; fracture healing; frozen shoulder; histology; joint mobility; Masson staining; nonhuman; parallel design; postoperative complication; potential difference; range of motion; rat; rat model; rotator cuff repair; rotator cuff rupture; scar tissue; Sprague Dawley rat; tendon adhesion; tissue expansion; vascularization; animal; disease model; drug effect; drug therapy; etiology; male; prevention and control; range of motion; rotator cuff; rotator cuff injury; Sprague Dawley rat; surgery; tissue adhesion; topical drug administration; wound healing ⓘ English 2024 2024-08 10.1016/j.arthro.2024.01.027 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Differential effect of cancer-associated fibroblast-derived extracellular vesicles on cisplatin resistance in oral squamous cell carcinoma via miR-876-3p ⓘ Rationale: Platinum-based chemotherapy is commonly used for treating solid tumors, but drug resistance often limits its effectiveness. Cancer-associated fibroblast (CAF)-derived extracellular vesicle (EV), which carry various miRNAs, have been implicated in chemotherapy resistance. However, the molecular mechanism through which CAFs modulate cisplatin resistance in oral squamous cell carcinoma (OSCC) is not well understood. We employed two distinct primary CAF types with differential impacts on cancer progression: CAF-P, representing a more aggressive cancer-promoting category, and CAF-D, characterized by properties that moderately delay cancer progression. Consequently, we sought to investigate whether the two CAF types differentially affect cisplatin sensitivity and the underlying molecular mechanism. Methods: The secretion profile was examined by utilizing an antibody microarray with conditioned medium obtained from the co-culture of OSCC cells and two types of primary CAFs. The effect of CAF-dependent factors on cisplatin resistance was investigated by utilizing conditioned media (CM) and extracellular vesicle (EVs) derived from CAFs. The impacts of candidate genes were confirmed using gain -and loss-of-function analyses in spheroids and organoids, and a mouse xenograft. Lastly, we compared the expression pattern of the candidate genes in tissues from OSCC patients exhibiting different responses to cisplatin.Results: When OSCC cells were cultured with conditioned media (CM) from the two different CAF groups, cisplatin resistance increased only under CAF-P CM. OSCC cells specifically expressed insulin-like growth factor binding protein 3 (IGFBP3) after co-culture with CAF-D. Meanwhile, IGFBP3-knockdown OSCC cells acquired cisplatin resistance in CAF-D CM. IGFBP3 expression was promoted by GATA-binding protein 1 (GATA1), a transcription factor targeted by miR-876-3p, which was enriched only in CAF-P-derived EV. Treatment with CAF-P EV carrying miR-876-3p antagomir decreased cisplatin resistance compared to control miRNA-carrying CAF-P EV. On comparing the staining intensity between cisplatin-sensitive and -insensitive tissues from OSCC patients, there was a positive correlation between IGFBP3 and GATA1 expression and cisplatin sensitivity in OSCC tissues from patients.Conclusion: These results provide insights for overcoming cisplatin resistance, especially concerning EVs within the tumor microenvironment. Furthermore, it is anticipated that the expression levels of GATA1 and miR-876-3p, along with IGFBP3, could aid in the prediction of cisplatin resistance. ⓘ Kang, Soo Hyun; Oh, Su Young; Lee, Kah-Young; Lee, Heon-Jin; Kim, Mee-Seon; Kwon, Tae-Geon; Kim, Jin-Wook; Lee, Sung-Tak; Choi, So -Young; Hong, Su-Hyung ⓘ Kyungpook Natl Univ, Sch Dent, Dept Microbiol & Immunol, Daegu 700412, South Korea; Kyungpook Natl Univ, Sch Dent, Dept Oral Pathol, Daegu 700412, South Korea; Kyungpook Natl Univ, Sch Dent, Dept Oral & Maxillofacial Surg, Daegu 700412, South Korea ⓘ ⓘ 57204021325; 57204016703; 57226450171; 36462383000; 56123006700; 35205433300; 55862646000; 55931708300; 57202918688; 8691449100 ⓘ dentalchoi@knu.ac.kr;hongsu@knu.ac.kr; ⓘ THERANOSTICS ⓘ THERANOSTICS ⓘ 1838-7640 14 2 SCIE MEDICINE, RESEARCH & EXPERIMENTAL ⓘ 2024 13.3 3.3 13.43 2025-04-16 ⓘ 16 16 cisplatin resistance; cancer-associated fibroblasts; extracellular vesicles; insulin-like growth factor binding protein 3; hsa-miR-876-3p ⓘ GROWTH-FACTOR-I; TUMOR MICROENVIRONMENT; PLASMA-LEVELS; EXOSOMES; HEAD; CHEMORESISTANCE; MECHANISMS; EXPRESSION; PATHWAY; RISK ⓘ cancer-associated fibroblasts; cisplatin resistance; extracellular vesicles; hsa-miR-876-3p; insulin-like growth factor binding protein 3 ⓘ Animals; Cancer-Associated Fibroblasts; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Culture Media, Conditioned; Extracellular Vesicles; Head and Neck Neoplasms; Humans; Mice; MicroRNAs; Mouth Neoplasms; Squamous Cell Carcinoma of Head and Neck; Tumor Microenvironment; 3,3' (1,4 phenylene)bis[n [4 (4,5 dihydro 1h imidazol 2 yl)phenyl]acrylamide]; antagomir; cisplatin; messenger RNA; microRNA; microRNA 876 3p; somatomedin binding protein 3; transcription factor GATA 1; unclassified drug; cisplatin; microRNA; MIRN876 microRNA, human; animal experiment; animal model; animal tissue; Article; cancer associated fibroblast; cancer patient; cell viability; clinical article; coculture; controlled study; down regulation; drug efficacy; drug mechanism; drug resistance; drug response; drug sensitivity; exosome; FaDu cell line; fibroblast culture; GATA1 gene; gene expression; gene knockdown; human; human cell; human tissue; IGFBP3 gene; in vitro study; in vivo study; monotherapy; mouse; mouth squamous cell carcinoma; nonhuman; organoid; prediction; protein expression; transcription regulation; tumor microenvironment; tumor spheroid; tumor xenograft; UM-SCC-1 cell line; upregulation; animal; cell proliferation; genetics; head and neck squamous cell carcinoma; head and neck tumor; metabolism; mouth tumor; pathology; pharmacology; squamous cell carcinoma; tumor cell line ⓘ English 2024 2024 10.7150/thno.87329 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Edoxaban for the treatment of hypercoagulability and cerebral thromboembolism associated with cancer: A randomized clinical trial of biomarker targets ⓘ Background: This study aimed compare efficacy of edoxaban and enoxaparin upon biomarkers of hypercoagulability in patients with cancer-related embolic stroke of undetermined source (ESUS).Methods: In this open-label, randomized, pilot trial, patients with cancer-related ESUS within 30 days of diagnosis were randomly assigned (1:1) to receive edoxaban (60 mg once daily) or enoxaparin (1 mg/kg twice daily) for 90 days. The primary endpoint was interval change of serum D-dimer level between days 0 and 7. The secondary endpoints were microembolic signals detected by transcranial Doppler at 7 and 90 days, the modified Rankin scale score, and stroke recurrence during 90 days. Safety outcomes included major bleeding and all-cause death at 90 days.Results: Of 303 patients with ischemic stroke and cancer, 40 fully met enrollment criteria and were randomized. Baseline D-dimer levels were numerically higher in the edoxaban group (22.9 +/- 15.9 mu g/mL vs 16.9 +/- 16.9 mu g/mL). D-dimer level change (%) between days 0 and 7 was similar in the two groups (53.2 +/- 25.7 vs 52.2 +/- 52.0; P = 0.11). Microembolic signals were detected in 41.1% and 43.8% at baseline, 41.2% and 42.9% at day 7, and 25.0% and 28.6% at day 90 in the edoxaban and enoxaparin groups, respectively. Non-significantly higher major bleeding (35.0% vs 10.0%, P = 0.06) and 90-day mortality (40.0% vs 25.0%, P = 0.31) were noted in the edoxaban group.Conclusion: Edoxaban and enoxaparin were comparable with respect to the biomarkers of hypercoagulability and cerebral thromboembolism. Larger trials are warranted to compare effects of edoxaban and enoxaparin upon recurrent stroke and major bleeding in patients with cancer-related ESUS.Trial registration: clinicaltrials.gov Identifier: NCT03570281 (https://clinicaltrials.gov/ct2/show/NCT03570281) ⓘ Chung, Jong-Won; Hwang, Jaechun; Kim, Hyung Jun; Seo, Woo-Keun; Ahn, Myung-Ju; Saver, Jeffrey L.; Bang, Oh Young ⓘ Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Neurol, 81 Irwon Ro, Seoul 06351, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Neurol, Daegu, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Div Hematol Oncol, Sch Med, Seoul, South Korea; Univ Calif Los Angeles, Dept Neurol, UCLA, Los Angeles, CA USA ⓘ Saver, Jeffrey/AFT-4279-2022 ⓘ 55553751200; 54980345300; 55635231700; 22981667600; 7103352186; 57201507502; 7006620221 ⓘ ohyoung.bang@samsung.com; ⓘ INTERNATIONAL JOURNAL OF STROKE ⓘ INT J STROKE ⓘ 1747-4930 1747-4949 19 6 SCIE CLINICAL NEUROLOGY;PERIPHERAL VASCULAR DISEASE ⓘ 2024 8.7 3.3 2.5 2025-05-07 ⓘ 6 6 Stroke; ischemic; thromboembolism; anticoagulants; biomarkers; enoxaparin; edoxaban ⓘ ISCHEMIC-STROKE ⓘ anticoagulants; biomarkers; edoxaban; enoxaparin; ischemic; Stroke; thromboembolism ⓘ Aged; Anticoagulants; Biomarkers; Enoxaparin; Factor Xa Inhibitors; Female; Fibrin Fibrinogen Degradation Products; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Pyridines; Thiazoles; Thrombophilia; Treatment Outcome; edoxaban; enoxaparin; fibrinogen; tissue plasminogen activator; anticoagulant agent; biological marker; blood clotting factor 10a inhibitor; edoxaban; enoxaparin; fibrin degradation product; fibrin fragment D; pyridine derivative; thiazole derivative; activated partial thromboplastin time; adult; aged; anemia; anticoagulation; Article; atherosclerosis; atrial fibrillation; blood clot lysis; brain hemorrhage; brain infarction; cardioembolic stroke; cerebral thromboembolism; cerebral thromboembolism; controlled study; creatinine clearance; diffusion weighted imaging; drug efficacy; heart valve replacement; human; hypercoagulability; hyperlipidemia; hypertension; ischemic stroke; lacunar infarction; low drug dose; lung embolism; major bleeding; male; malignant neoplasm; mitral valve stenosis; multicenter study; nuclear magnetic resonance imaging; pilot study; prothrombin time; randomized controlled trial; Rankin scale; thrombocytopenia; thromboembolism; blood; complication; drug therapy; etiology; female; metabolism; middle aged; neoplasm; thrombophilia; treatment outcome ⓘ English 2024 2024-07 10.1177/17474930241239266 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Review ⓘ Exploration of metal-free 2D electrocatalysts toward the oxygen electroreduction ⓘ The advancement of economical and readily available electrocatalysts for the oxygen reduction reaction (ORR) holds paramount importance in the advancement of fuel cells and metal-air batteries. Recently, 2D non-metallic materials have obtained substantial attention as viable alternatives for ORR catalysts due to their manifold advantages, encompassing low cost, ample availability, substantial surface-to-volume ratio, high conductivity, exceptional durability, and competitive activity. The augmented ORR performances observed in metal-free 2D materials typically arise from heteroatom doping, defects, or the formation of heterostructures. Here, the authors delve into the realm of electrocatalysts for the ORR, pivoting around metal-free 2D materials. Initially, the merits of metal-free 2D materials are explored and the reaction mechanism of the ORR is dissected. Subsequently, a comprehensive survey of diverse metal-free 2D materials is presented, tracing their evolutionary journey from fundamental concepts to pragmatic applications in the context of ORR. Substantial importance is given on the exploration of various strategies for enhancing metal-free 2D materials and assessing their impact on inherent material performance, including electronic properties. Finally, the challenges and future prospects that lie ahead for metal-free 2D materials are underscored, as they aspire to serve as efficient ORR electrocatalysts. This review presents recent advances in metal-free 2D materials for the oxygen reduction reaction (ORR), covering mechanistic insights, catalyst development, and performance enhancement. It also addresses challenges and future prospects for the development of high-performance metal-free 2D electrocatalysts toward the ORR. image ⓘ Kundu, Joyjit; Kwon, Taehyun; Lee, Kwangyeol; Choi, Sang-Il ⓘ Kyungpook Natl Univ, Dept Chem, Daegu 41566, South Korea; Kyungpook Natl Univ, Green Nano Mat Res Ctr, Daegu 41566, South Korea; Incheon Natl Univ, Dept Chem, Incheon, South Korea; Incheon Natl Univ, Res Inst Basic Sci, Incheon, South Korea; Korea Univ, Dept Chem, Seoul 02841, South Korea; Korea Univ, Res Inst Nat Sci, Seoul 02841, South Korea ⓘ Kundu, Joyjit/AAY-7466-2021; Choi, Sang-Il/N-7571-2013; Chung, Chan-Hwa/D-5194-2011; Kwon, Taehyun/AAH-9830-2021; Choi, Sangil/N-7571-2013 ⓘ 57209325902; 57190672792; 8510322900; 56167600800 ⓘ kylee1@korea.ac.kr;sichoi@knu.ac.kr; ⓘ EXPLORATION ⓘ EXPLORATION-PRC ⓘ 2766-8509 2766-2098 4 4 ESCI MATERIALS SCIENCE, MULTIDISCIPLINARY;MULTIDISCIPLINARY SCIENCES;NANOSCIENCE & NANOTECHNOLOGY ⓘ 2024 22.5 3.3 3.37 2025-05-07 ⓘ 18 17 2D materials; electrocatalysts; non-metal; oxygen reduction reaction ⓘ NITROGEN-DOPED GRAPHENE; REDUCTION REACTION; CARBON NANOSHEETS; ELECTRON-TRANSFER; FREE CATALYSTS; BLACK PHOSPHORUS; CARRIER MOBILITY; ACTIVITY ORIGIN; BORON; NITRIDE ⓘ 2D materials; electrocatalysts; non-metal; oxygen reduction reaction ⓘ ⓘ English 2024 2024-08 10.1002/exp.20220174 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Highly potent and selective PPAR6 agonist reverses memory deficits in mouse models of Alzheimer's disease ⓘ Rationale: Alzheimer's disease (AD) is a progressive neurodegenerative disease accompanied by neurotoxicity, excessive inflammation, and cognitive impairment. The peroxisome proliferator-activated receptor (PPAR) 6 is a potential target for AD. However, its regulatory mechanisms and therapeutic potential in AD remain unclear. We aimed to investigate if the activation of PPAR6 using a highly selective and potent agonist could provide an effective therapeutic strategy against AD. Methods: We synthesized a novel PPAR6 agonist, 5a, containing a selenazole group and determined the X-ray crystal structure of its complex with PPAR6. The drug-like properties of 5a were assessed by analyzing cytochrome P450 (CYP) inhibition, microsomal stability, pharmacokinetics, and mutagenicity. We investigated the anti-inflammatory effects of 5a using lipopolysaccharide (LPS)-stimulated BV-2 microglia and neuroinflammatory mouse model. The therapeutic efficacy of 5a was evaluated in AD mice with scopolamine-induced memory impairment and APP/PS1 by analyzing cognitive function, glial reactivity, and amyloid pathology. Results: Compound 5a , the most potent and selective PPAR6 agonist, was confirmed to bind hPPAR6 in a complex by X-ray crystallographic analysis. PPAR6 activation using 5a showed potent anti-inflammatory effects in activated glial cells and mouse model of neuroinflammation. Administration of 5a inhibited amyloid plaque deposition by suppressing the expression of neuronal beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), and reduced abnormal glial hyperactivation and inflammatory responses, resulting in improved learning and memory in the APP/PS1 mouse model of AD. Conclusion: We identified that specific activation of PPAR6 provides therapeutic effects on multiple pathogenic phenotypes of AD, including neuroinflammation and amyloid deposition. Our findings suggest the potential of PPAR6 as a promising drug target for treating AD. ⓘ Kim, Hyeon Jeong; Kim, Haelee; Song, Jaeyoung; Hong, Jun Young; Lee, Elijah Hwejin; Londhe, Ashwini M.; Choi, Ji Won; Park, Sun Jun; Oh, Eunseok; Yoon, Heeseok; Hwang, Hoosang; Hahn, Dongyup; Jung, Kyungjin; Kwon, Sugyeong; Kadayat, Tara Man; Ma, Min Jung; Joo, Jeongmin; Kim, Jina; Bae, Jae Hyun; Hwang, Hayoung; Pae, Ae Nim; Cho, Sung Jin; Park, Jong-Hyun; Chin, Jungwook; Kang, Heonjoong; Park, Ki Duk ⓘ Korea Inst Sci & Technol KIST, Ctr Brain Disorders, Seoul 02792, South Korea; Daegu Gyeongbuk Med Innovat Fdn, New Drug Dev Ctr, Daegu 41061, South Korea; Seoul Natl Univ, Sch Earth & Environm Sci, Lab Marine Drugs, NS-80, Seoul 08826, South Korea; Yonsei Univ, Dept Syst Biol, Seoul 03722, South Korea; Korea Univ Sci & Technol, KIST Sch, Div Biomed Sci & Technol, Seoul 02792, South Korea; Cureverse lnc, KIST, H2 Bldg, Seoul 02792, South Korea; Kyungpook Natl Univ, Sch Food Sci & Biotechnol, Daegu 41566, South Korea; Seoul Natl Univ, Res Inst Oceanog, NS-80, Seoul 08826, South Korea ⓘ Hong, JunYoung/KRP-5505-2024; Bae, Jae/AAH-6610-2019; Londhe, Ashwini/S-1211-2019 ⓘ 57198434218; 59346285200; 56184911300; 37053789300; 57209332048; 55537809100; 56082603800; 57211413376; 57215043093; 57192176135; 23090783800; 36554163400; 57203728292; 56645470600; 50461633400; 57192190657; 55523795900; 56949261900; 59346369000; 57112963600; 6701727840; 58735369700; 56815989600; 36554007700; 7404070913; 57191756606 ⓘ jhyunprk@kist.re.kr;jwchin@kist.re.kr;hjkang@snu.ac.kr;kdpark@kist.re.kr; ⓘ THERANOSTICS ⓘ THERANOSTICS ⓘ 1838-7640 14 16 SCIE MEDICINE, RESEARCH & EXPERIMENTAL ⓘ 2024 13.3 3.3 0 2025-05-07 ⓘ 0 0 PPAR delta agonist; Alzheimer's disease; anti-inflammation; glial activation; BACE1 ⓘ PROLIFERATOR-ACTIVATED RECEPTOR; KAPPA-B ACTIVITY; TRANSCRIPTION FACTORS; CYTOKINE PRODUCTION; BETA/DELTA AGONIST; NUCLEAR RECEPTORS; INFLAMMATION; DELTA; BRAIN; DYSFUNCTION ⓘ Alzheimer’s disease; anti-inflammation; BACE1; glial activation; PPARδ agonist ⓘ Alzheimer Disease; Animals; Disease Models, Animal; Humans; Male; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Neuroinflammatory Diseases; PPAR delta; acetic acid derivative; amyloid beta protein; cytochrome P450; cytochrome P450 1A2; cytochrome P450 2C19; cytochrome P450 2C9; cytochrome P450 2D6; cytochrome P450 3A4; dextromethorphan; lipopolysaccharide; macrogol 400; mephenytoin; midazolam; nitric oxide; peroxisome proliferator activated receptor delta agonist; phenacetin; scopolamine; tumor necrosis factor; unclassified drug; {2 methyl 4 [4 methyl 2 (4 trifluoromethyl phenyl) selenazol 5 yl methylselanyl] phenoxy} acetic acid; {2 methyl 4 [4 methyl 2 (4 trifluoromethyl phenyl) selenazol 5 yl methylsulfanyl] phenoxy} acetic acid; peroxisome proliferator activated receptor delta; Alzheimer disease; Ames test; amnesia; animal cell; animal experiment; animal model; animal tissue; antioxidant activity; anxiety; Article; carbon nuclear magnetic resonance; cognitive defect; column chromatography; controlled study; crystal structure; crystallization; cytotoxicity; degenerative disease; EC50; electrospray mass spectrometry; enzyme linked immunosorbent assay; Escherichia coli; fluorescence polarization; genetic transfection; glia cell; high performance liquid chromatography; hippocampus; hydrogen bond; IC50; immobility time; immunofluorescence; immunoreactivity; inflammation; liver microsome; male; mass spectrometry; memory; metabolic stability; microglia; Morris water maze test; mouse; mutagenicity; nervous system inflammation; nonhuman; open field test; particle size; passive avoidance test; phagocytosis; pharmacokinetic parameters; polarization; protein purification; proton nuclear magnetic resonance; radioimmunoprecipitation; rat; real time reverse transcription polymerase chain reaction; SH-SY5Y cell line; spatial learning; thin layer chromatography; Western blotting; working memory; X ray crystallography; Y-maze test; animal; C57BL mouse; disease model; drug effect; drug therapy; human; memory disorder; metabolism; transgenic mouse ⓘ English 2024 2024 10.7150/thno.96707 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ IL4 receptor targeting enables nab-paclitaxel to enhance reprogramming of M2-type macrophages into M1-like phenotype via ROS-HMGB1-TLR4 axis and inhibition of tumor growth and metastasis ⓘ Rationale: Nab-paclitaxel (Abx) is widely employed in malignant tumor therapy. In tumor cells and protumoral M2 -type macrophages, the IL4 receptor (IL4R) is upregulated. This study aimed to elucidate the selective delivery of Abx to M2 -type macrophages by targeting IL4R and reprogramming them into an antitumoral M1 -type. Methods: Abx was conjugated with the IL4R-binding IL4RPep-1 peptide using click chemistry (IL4R-Abx). Cellular internalization, macrophage reprogramming and signal pathways, and tumor growth and metastasis by IL4R-Abx were examined. Results: IL4R-Abx was internalized into M2 macrophages more efficiently compared to the unmodified Abx and control peptide -conjugated Abx (Ctrl-Abx), which was primarily inhibited using an anti-IL4R antibody and a receptor -mediated endocytosis inhibitor compared with a macropinocytosis inhibitor. IL4R-Abx reprogrammed the M2 -type macrophages into M1 -like phenotype and increased reactive oxygen species (ROS) levels and extracellular release of high mobility group box 1 (HMGB1) in M2 macrophages at higher levels than Abx and Ctrl-Abx. The conditioned medium of IL4R-Abx-treated M2 macrophages skewed M2 macrophages into the M1 -like phenotype, in which an anti-HMGB1 antibody and a toll -like receptor 4 (TLR4) inhibitor induced a blockade. IL4R-Abx accumulated at tumors, heightened immune -stimulatory cells while reducing immune -suppressing cells, and hampered tumor growth and metastasis in mice more efficiently than Abx and Ctrl-Abx. Conclusions: These results indicate that IL4R-targeting allows enhancement of M2 -macrophage shaping into M1 -like phenotype by Abx through the ROS-HMGB1-TLR4 axis, improvement of antitumor immunity, and thereby inhibition of tumor growth and metastasis, presenting a new approach to cancer immunotherapy. ⓘ Vadevoo, Sri Murugan Poongkavithai; Kang, Yeoul; Gunassekaran, Gowri Rangaswamy; Lee, Seok-Min; Park, Min-Sung; Jo, Dong Gyun; Kim, Sang-Kyun; Lee, Ho; Kim, Won Jong; Lee, Byungheon ⓘ Kyungpook Natl Univ, Sch Med, Dept Biochem & Cell Biol, 680 Gukchaebosang Ro, Daegu 41944, South Korea; Kyungpook Natl Univ, Sch Med, Dept Biomed Sci, 680 Gukchaebosang Ro, Daegu 41944, South Korea; Kyungpook Natl Univ, Sch Med, CMRI, 680 Gukchaebosang Ro, Daegu 41944, South Korea; Pohang Univ Sci & Technol POSTECH, POSTECH CATHOLIC Biomed Engn Inst, Dept Chem, 77 Cheongam Ro, Pohang 37673, Gyeongbuk, South Korea; K Medi Hub, Lab Anim Ctr, 88 Dongnae Ro, Daegu 41061, South Korea; Natl Canc Ctr, Lab Anim Res Facil, 323 Ilsan Ro, Koyang 10408, Kyunggi, South Korea ⓘ kim, juhee/HKV-6163-2023 ⓘ 56663280000; 57216508987; 36028043400; 58297098600; 58996258200; 58996635100; 58996994600; 58996994700; 7405810991; 16304374900 ⓘ wjkim@postech.ac.kr;leebh@knu.ac.kr; ⓘ THERANOSTICS ⓘ THERANOSTICS ⓘ 1838-7640 14 6 SCIE MEDICINE, RESEARCH & EXPERIMENTAL ⓘ 2024 13.3 3.3 7.23 2025-04-16 ⓘ 13 14 IL4 receptor; M2-macrophage; nab-paclitaxel; reprogramming; immunotherapy ⓘ INTERLEUKIN-4 RECEPTOR; ANTITUMOR-ACTIVITY; CELLS; CANCER; THERAPEUTICS; PROGRESSION; ACTIVATION; MECHANISMS; EXPRESSION; DELIVERY ⓘ IL4 receptor; immunotherapy; M2-macrophage; nab-paclitaxel; reprogramming ⓘ Albumins; Animals; HMGB1 Protein; Mice; Neoplasms; Paclitaxel; Peptides; Phenotype; Reactive Oxygen Species; Toll-Like Receptor 4; high mobility group B1 protein; interleukin 4 antibody; interleukin 4 receptor; paclitaxel; reactive oxygen metabolite; toll like receptor 4; 130-nm albumin-bound paclitaxel; albumin; high mobility group B1 protein; paclitaxel; peptide; reactive oxygen metabolite; toll like receptor 4; animal cell; animal experiment; animal model; animal tissue; antineoplastic activity; Article; breast tumor; cancer immunotherapy; cancer inhibition; chemical structure; click chemistry; controlled study; cytotoxicity; endocytosis; ex vivo study; histology; immunocompetent cell; internalization (cell); lung tumor; M1 macrophage; M2 macrophage; metastasis; monocyte; mouse; nonhuman; pancreas tumor; phenotype; protein targeting; real time reverse transcription polymerase chain reaction; signal transduction; upregulation; animal; neoplasm; phenotype ⓘ English 2024 2024 10.7150/thno.92672 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Impact of intensive blood pressure lowering after multiple-attempt endovascular thrombectomy: A secondary analysis of the OPTIMAL-BP trial ⓘ Background: Multiple attempts of thrombectomy have been linked to a higher risk of intracerebral hemorrhage and worsened functional outcomes, potentially influenced by blood pressure (BP) management strategies. Nonetheless, the impact of intensive BP management following successful recanalization through multiple attempts remains uncertain. Aims: This study aimed to investigate whether conventional and intensive BP managements differentially affect outcomes according to multiple-attempt recanalization (MAR) and first-attempt recanalization (FAR) groups. Methods: In this secondary analysis of the OPTIMAL-BP trial, which was a comparison of intensive (systolic BP target: <140 mm Hg) and conventional (systolic BP target=140-180 mm Hg) BP managements during the 24 h after successful recanalization, we included intention-to-treat population of the trial. Patients were divided into the MAR and the FAR groups. We examined a potential interaction between the number of thrombectomy attempts (MAR and FAR groups) and the effect of BP managements on clinical and safety outcomes. The primary outcome was functional independence at 3months. Safety outcomes were symptomatic intracerebral hemorrhage within 36 h and mortality within 3 months. Results: Of the 305 patients (median=75 years), 102 (33.4%) were in the MAR group and 203 (66.6%) were in the FAR group. The intensive BP management was significantly associated with a lower rate of functional independence in the MAR group (intensive, 32.7% vs conventional, 54.9%, adjusted odds ratio (OR)=0.33, 95% confidence interval (CI)=0.12-0.90, p=0.03). In the FAR group, the proportion of patients with functional independence was not significantly different between the BP managements (intensive, 42.5% vs conventional, 54.2%, adjusted OR=0.73, 95% CI=0.38-1.40). Incidences of symptomatic intracerebral hemorrhage and mortality rates were not significantly different according to the BP managements in both MAR and FAR groups. Conclusions: Among stroke patients who received multiple attempts of thrombectomy, intensive BP management for 24h resulted in a reduced chance of functional independence at 3months and did not reduce symptomatic intracerebral hemorrhage following successful reperfusion. ⓘ Jung, Jae Wook; Kim, Kwang Hyun; Yun, Jaeseob; Kim, Young Dae; Heo, JoonNyung; Lee, Hyungwoo; Choi, Jin Kyo; Lee, Il Hyung; Lim, In Hwan; Hong, Soon-Ho; Kim, Byung Moon; Kim, Dong Joon; Shin, Na Young; Cho, Bang-Hoon; Ahn, Seong Hwan; Park, Hyungjong; Sohn, Sung-Il; Hong, Jeong-Ho; Song, Tae-Jin; Chang, Yoonkyung; Kim, Gyu Sik; Seo, Kwon-Duk; Lee, Kijeong; Chang, Jun Young; Seo, Jung Hwa; Lee, Sukyoon; Baek, Jang-Hyun; Cho, Han-Jin; Shin, Dong Hoon; Kim, Jinkwon; Yoo, Joonsang; Baik, Minyoul; Lee, Kyung-Yul; Jung, Yo Han; Hwang, Yang-Ha; Kim, Chi Kyung; Kim, Jae Guk; Lee, Chan Joo; Park, Sungha; Jeon, Soyoung; Lee, Hye Sun; Kwon, Sun U.; Bang, Oh Young; Heo, Ji Hoe; Nam, Hyo Suk ⓘ Yonsei Univ, Dept Neurol, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea; Yonsei Univ, Dept Radiol, Coll Med, Seoul, South Korea; Korea Univ, Dept Neurol, Anam Hosp, Seoul, South Korea; Korea Univ, Dept Neurol, Coll Med, Seoul, South Korea; Chosun Univ, Dept Neurol, Sch Med, Gwangju, South Korea; Keimyung Univ, Brain Res Inst, Dept Neurol, Sch Med, Daegu, South Korea; Ewha Womans Univ, Coll Med, Dept Neurol, Seoul Hosp, Seoul, South Korea; Ewha Womans Univ, Mokdong Hosp, Dept Neurol, Coll Med, Seoul, South Korea; Ilsan Hosp, Natl Hlth Insurance Serv, Goyang, South Korea; Univ Ulsan, Dept Neurol, Asan Med Ctr, Coll Med, Seoul, South Korea; Inje Univ, Busan Paik Hosp, Dept Neurol, Coll Med, Busan, South Korea; Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Neurol, Sch Med, Seoul, South Korea; Pusan Natl Univ, Dept Neurol, Sch Med, Busan, South Korea; Gachon Univ, Dept Neurol, Gil Med Ctr, Incheon, South Korea; Yonsei Univ, Yongin Severance Hosp, Dept Neurol, Coll Med, Yongin, South Korea; Yonsei Univ, Gangnam Severance Hosp, Dept Neurol, Coll Med, Seoul, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Neurol, Daegu, South Korea; Korea Univ, Dept Neurol, Guro Hosp, Seoul, South Korea; Korea Univ, Dept Neurol, Coll Med, Seoul, South Korea; Eulji Univ, Daejeon Eulji Med Ctr, Dept Neurol, Sch Med, Daejeon, South Korea; Yonsei Univ, Severance Hosp, Dept Hlth Promot, Coll Med, Seoul, South Korea; Yonsei Univ, Res Inst, Coll Med, Seoul, South Korea; Yonsei Univ, Biostat Collaborat Unit, Dept Res Affairs, Coll Med, Seoul, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Neurol, Sch Med, Seoul, South Korea ⓘ Seo, Kwonduk/HLG-9100-2023; Kim, Jinkwon/AAR-6729-2021; Hong, Jeong-Ho/T-8099-2018; Lee, Jeong Hoon/AAF-2400-2020; Kim, Chi/AAR-9819-2020; Heo, JoonNyung/ABI-5389-2020; Yun, Jaeseob/LOS-5991-2024; kim, deog young/Q-8498-2019; Lee, HS/AAD-6757-2019; CHIA, YOOK CHIN/B-8379-2010; Kim, Dong/AAH-2257-2021; Lee, Hye/J-2154-2015; Park, Hyungjong/AAI-5361-2020; Seo, Jung/N-2344-2017; Kim, Ji-Young/HJA-5494-2022; Kim, Jinkwon/N-1878-2018; Lee, Kyung-Yul/KVZ-0950-2024; Lee, Jongmin/Q-4909-2019 ⓘ 57217003257; 57209600032; 58905434900; 57293047300; 57219861395; 57209973874; 57215910153; 59251310000; 57214234925; 58312729300; 49861594200; 57965484900; 56363572300; 55171752400; 57200401172; 57199865406; 36479287000; 55931654800; 55507164200; 56525550900; 57204440618; 57219304565; 56101426700; 56346807100; 55471870500; 57217310224; 56066538700; 57211361916; 57222389564; 37090736900; 55261162200; 57197951986; 57306378900; 57217582769; 7402311308; 56701057800; 56720623400; 57226133622; 8556278400; 57223622373; 57208650357; 7402624264; 59250606100; 34869576000; 58719143100 ⓘ hsnam@yuhs.ac; ⓘ INTERNATIONAL JOURNAL OF STROKE ⓘ INT J STROKE ⓘ 1747-4930 1747-4949 19 10 SCIE CLINICAL NEUROLOGY;PERIPHERAL VASCULAR DISEASE ⓘ 2024 8.7 3.3 0.62 2025-05-07 ⓘ 1 1 Endovascular thrombectomy; blood pressure; cerebral infarction; thrombectomy attempt ⓘ ACUTE ISCHEMIC-STROKE; MECHANICAL THROMBECTOMY; REPERFUSION; RETRIEVER; TIME ⓘ blood pressure; cerebral infarction; Endovascular thrombectomy; thrombectomy attempt ⓘ Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cerebral Hemorrhage; Endovascular Procedures; Female; Humans; Hypertension; Male; Middle Aged; Stroke; Thrombectomy; Treatment Outcome; nicardipine; antihypertensive agent; adult; aged; Article; atrial fibrillation; blood pressure; brain hemorrhage; computed tomographic angiography; congestive heart failure; controlled study; diabetes mellitus; European Quality of Life 5 Dimensions 3 Level questionnaire; female; human; hyperlipidemia; hypertension; intensive blood pressure; magnetic resonance angiography; major clinical study; male; mortality rate; multiple attempt endovascular thrombectomy; National Institutes of Health Stroke Scale; percutaneous thrombectomy; Rankin scale; recanalization; smoking; systolic blood pressure; brain hemorrhage; cerebrovascular accident; endovascular surgery; middle aged; physiology; procedures; randomized controlled trial; surgery; therapy; thrombectomy; treatment outcome; very elderly ⓘ English 2024 2024-12 10.1177/17474930241265652 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Mucoadhesive chitosan microcapsules for controlled gastrointestinal delivery and oral bioavailability enhancement of low molecular weight peptides ⓘ A bioactive compound, collagen peptide (CP), is widely used for biological activities such as anti-photoaging and antioxidant effects, with increased oral bioavailability because of its low molecular weight and high hydrophilicity. However, controlling release time and increasing retention time in the digestive tract for a more convenient oral administration is still a challenge. We developed CP-loaded chitosan (CS) microcapsules via strong and rapid ionic gelation using a highly negative phytic acid (PA) crosslinker. The platform enhanced the oral bioavailability of CP with controlled gastrointestinal delivery by utilizing the mucoadhesiveness and tight junction-opening properties of CS. CS and CP concentrations varied from 1.5 to 3.5% and 0-30%, respectively, for optimal and stable microcapsule synthesis. The physicochemical properties, in vitro release profile with in-testinal permeability, in vivo oral bioavailability, in vivo biodistribution, anti-photoaging effect, and antioxidant effect of optimized CS microcapsules were analyzed to investigate the impact of controlling parameters. The structure of CS microcapsules was tuned by PA diffused gradient ionic cross-linking degree, resulting in a controlled CP release region in the gastrointestinal tract. The optimized microcapsules increased Cmax, AUC, and tmax by 1.5-, 3.4-, and 8.0-fold, respectively. Furthermore, CP in microcapsules showed anti-photoaging effects by downregulating matrix metalloproteinases-1 via antioxidant effects. According to our knowledge, this is the first study to microencapsulate CP for oral bioavailability enhancement. The peptide delivery method employed is simple, economical, and can be applied to customize bioactive compound administration. ⓘ Yang, Kyungjik; Han, Hwa Seung; An, Seung Hwan; Park, Kyung Hoon; Nam, Keonwook; Hwang, Shinha; Lee, Yuyeon; Cho, Sung Yeon; Kim, Taehyung; Choe, Deokyeong; Kim, Sang Won; Yu, Wonkyu; Lee, Hyunah; Park, Jiyong; You, Sangguan; Jo, Dong- Gyu; Choi, Ki Young; Roh, Young Hoon; Park, Jae Hyung ⓘ Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biotechnol, 50 Yonsei Ro,Seodaemun Gu, Seoul 03722, South Korea; Yonsei Univ, Coll Life Sci & Biotechnol, Grad Program Bioind Engn, 50 Yonsei Ro,Seodaemun Gu, Seoul 03722, South Korea; Gangneung Wonju Natl Univ, Dept Marine Food Sci & Technol, Kangnung, South Korea; Kyungpook Natl Univ, Coll Agr & Life Sci, Sch Food Sci & Biotechnol, Daegu 41566, South Korea; Yonsei Univ, Dairy R&D Ctr, Asan, South Korea; Dongyang Mirae Univ, Dept Bioconvergence Engn, 445-8,Gyeongin Ro,Guro Gu, Seoul 02841, South Korea; Nutrex Technol, 670 Daewangpangyo Ro, Seongnam 13494, South Korea; Sungkyunkwan Univ, Sch Pharm, Suwon 16419, South Korea; Sungkyunkwan Univ, SAIHST, Dept Hlth Sci & Technol, Seoul 06351, South Korea; Sungkyunkwan Univ, Biomed Inst Convergence SKKU BICS, Suwon 16419, South Korea; Gangneung Wonju Natl Univ, East Coast Res Inst Life Sci, 120 Gangneung, Kangnung 210702, Gangwon Do, South Korea; Sungkyunkwan Univ, Sch Chem Engn, Suwon 16419, South Korea ⓘ Park, Jae/B-5967-2018; Kim, Sang-Won/AAC-5429-2019; CHOI, KI YOUNG/Q-7177-2016; 한, 화승/ABF-2380-2021; Roh, Young/N-6942-2016; Choe, Deokyeong/AAQ-1194-2020; Jo, Dong-Gyu/AAN-9278-2021 ⓘ 55791344100; 39661036000; 58728294300; 57576800500; 57196024280; 58726695900; 57560910400; 37664677100; 57221160613; 37074453400; 58729089300; 57215664840; 37665229200; 55716975100; 7201516866; 7006823770; 59253632700; 35879256200; 56113586400 ⓘ jodg@skku.edu;kiyoungchoi7@gmail.com;yr36@yonsei.ac.kr;jhpark1@skku.edu; ⓘ JOURNAL OF CONTROLLED RELEASE ⓘ J CONTROL RELEASE ⓘ 0168-3659 1873-4995 365 SCIE CHEMISTRY, MULTIDISCIPLINARY;PHARMACOLOGY & PHARMACY ⓘ 2024 11.5 3.3 6.52 2025-04-16 ⓘ 15 16 Collagen peptide; Chitosan; Microcapsule; Phytic acid; Controlled gastrointestinal delivery; Oral bioavailability ⓘ GLY-PRO-HYP; IN-VITRO; HYDROLYSATE LEADS; DRUG-DELIVERY; COLLAGEN; ENCAPSULATION; MICROENCAPSULATION; ACID; MICROPARTICLE; ABSORPTION ⓘ Chitosan; Collagen peptide; Controlled gastrointestinal delivery; Microcapsule; Oral bioavailability; Phytic acid ⓘ Administration, Oral; Antioxidants; Biological Availability; Capsules; Chitosan; Drug Carriers; Gastrointestinal Tract; Molecular Weight; Peptides; Tissue Distribution; Antioxidants; Biochemistry; Collagen; Gelation; Microstructure; Molecular weight; Peptides; Physicochemical properties; chitosan; collagen; collagen peptide; glyceraldehyde 3 phosphate dehydrogenase; interstitial collagenase; matrix metalloproteinase; peptide; phytic acid; unclassified drug; antioxidant; drug carrier; peptide; Antioxidant effect; Bioactive compounds; Bioavailability enhancements; Collagen peptides; Controled gastrointestinal delivery; Gastrointestinal; Microcapsules; Oral bioavailabilities; Photo-aging; Phytic acids; animal experiment; animal tissue; antioxidant activity; area under the curve; Article; concentration process; controlled study; cross linking; cytotoxicity; down regulation; drug bioavailability; drug delivery system; drug distribution; drug release; female; fluorescence microscopy; gastrointestinal tract; gelation; in vitro study; intestine cell; intestine mucosa permeability; maximum concentration; microcapsule; microencapsulation; molecular weight; mouth cavity; mucoadhesion; nonhuman; photoaging; physical chemistry; rat; scanning electron microscopy; sustained drug release; tight junction; time to maximum plasma concentration; bioavailability; chemistry; gastrointestinal tract; oral drug administration; tissue distribution; Chitosan ⓘ English 2024 2024-01 10.1016/j.jconrel.2023.10.021 ⓘ 바로가기 바로가기 바로가기 바로가기
페이지 이동: